Advertisement
Advertisement
U.S. Markets open in 5 hrs 20 mins
Advertisement
Advertisement
Advertisement
Advertisement

Tetra Bio-Pharma Inc. (TBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.04000.0000 (0.00%)
At close: 03:53PM EDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0400
Open0.0400
Bid0.0350 x N/A
Ask0.0400 x N/A
Day's Range0.0350 - 0.0400
52 Week Range0.0350 - 0.2900
Volume2,214,475
Avg. Volume310,960
Market Cap16.589M
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-0.1130
Earnings DateJul 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that the Company has revised the terms of its previously announced financing arrangement (the "Financing") with Global Corporate Finance Opportunities 16 (the "Investor"), an investment vehicle advised by Alpha Blue Ocean ("ABO"), and has closed the first tranche of the Financing on such revised terms, the whole pursuant to the term

  • CNW Group

    IIROC Trade Resumption - TBP

    Trading resumes in:

  • PR Newswire

    Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today they signed an agreement with Cellvera Global Holdings LLC ("Cellvera"), for the co-development of ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug.

Advertisement
Advertisement